A study co-authored by researchers from the University of Texas has found how certain cancers resist immunotherapy by preventing the immune system from activating. The team discovered that a key element of the immune system, NKG2A, cannot engage with cancer cells without a particular trigger, and the study’s findings could help develop more effective immunotherapy drugs.
FDA Approves Viridian’s Thyroid Eye Disease Drug, Competitor to a Blockbuster Amgen Med
Viridian Therapeutics’ Lumvoa is approved for treating both the chronic and active phases of thyroid eye disease. This drug will offer patients an alternative to
